Baseline characteristics of severe asthma patients initiating biologic treatment worldwide Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021
Effects of exacerbation risk on symptoms and clinical characteristics in patients with bronchiectasis Source: Annual Congress 2012 - Assessment of physical activity, exercise, muscle function and clinical characteristics as outcomes in physiotherapy and rehabilitation Year: 2012
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma Source: Eur Respir J, 58 (6) 2100413; 10.1183/13993003.00413-2021 Year: 2021
Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Patient baseline variables predict future asthma control status and risk of exacerbations Source: Annual Congress 2010 - Management of airway disease Year: 2010
Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials Source: Eur Respir J, 53 (5) 1900599; 10.1183/13993003.00599-2019 Year: 2019
Relationship between omalizumab efficacy and baseline allergen profile impacts patient-reported outcomes in allergic asthma Source: International Congress 2018 – Tests and trends in asthma Year: 2018
Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma Source: Eur Respir J, 58 (4) 2004605; 10.1183/13993003.04605-2020 Year: 2021
The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma Source: International Congress 2017 – Bronchial asthma management Year: 2017
Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007
Clinical and economic impact of an improvement in adherence based on specific attributes of single-inhaler triple therapies in COPD patients Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019
Real-world patient characteristics and eligibility for biologics in severe asthma (RECOGNISE) Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
Influence of statin therapy on clinical symptoms, severity and prognosis in patients with community acquired pneumonia Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008
The contribution of comorbidities, psychosocial factors and adherence to the presentation of severe asthma Source: Eur Respir Monogr 2019; 84: 30-47 Year: 2019
The clinical impact of adherence to therapy in airways disease Source: Breathe, 17 (2) 210039; 10.1183/20734735.0039-2021 Year: 2021
The impact of COVID-19 on patients with asthma Source: Eur Respir J, 57 (3) 2003142; 10.1183/13993003.03142-2020 Year: 2021
Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: the real-life data Source: International Congress 2018 – Tests and trends in asthma Year: 2018
Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Associations between clinical, laboratory and therapeutical parameters on admission and adverse outcomes in patients hospitalized for COPD exacerbations Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010
Acute exacerbation phenotypes of asthma and COPD: impact on clinical outcomes Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations Year: 2021